An initial small pilot study (IMMU-132) involving only six heavily pretreated patients with urothelial carcinoma included Trop-2 IHC testing on archival urothelial carcinoma specimens revealed a strong Trop-2 protein expression with a positive correlation to therapy response [59]. This evidence concerns the gene TACSTD2 and urothelial carcinoma.